Study with Us
graduate study at the department of oncology
We warmly invite you to join us for a unique opportunity to study with leading scientists in the field of oncology and radiation biology.
The Department offers an established, world-leading, graduate training programme. Our degree courses are a critical element in our drive to revolutionise training in radiation oncology and cancer research in the UK. We are striving to make advances in radiation biology and to translate these into improved clinical outcomes for cancer patients.
Please take a moment to review the different courses available in this department and to hear what our students really think on our Student Experience page.
- DPhil in Oncology
- MRes in Oncology
- MSc in Radiation Biology
- MSc in Precision Cancer Medicine (Part-time and online)
- MSc Experimental and Translational Therapeutics (Part-time, delivered in collaboration with the Department for Continuing Education)
Contact us at the Graduate Studies Office if you have more questions that are not answered here.
Professor Tim Maughan outlines the flagship work of the FOCUS4 trials, whose results were presented this weekend at the European Society of Medical Oncology (ESMO) annual meeting
New blood-based test is the first ever to simultaneously identify if a patient has cancer and if it has spread
5 January 2022
A publication by University of Oxford researchers describes a new minimally invasive and inexpensive blood test that can identify cancer in patients with non-specific symptoms. The early success of this technology makes it the first blood-based test that not only detects cancer in this population but can simultaneously identify if a cancer has spread.
16 December 2021
Eileen is awarded funding for her research into the tumour microenvironment
26 November 2021
Anneliese Dodds, MP for Oxford East & Chair of the Labour Party, visited the University of Oxford to learn more about the impactful work happening across departments in the field of cancer research.
World’s first cancer prevention trial to test diabetes drug in patients with high-risk genetic condition
24 November 2021
Oxford researchers will lead a £2m national cancer prevention trial to assess the benefit a diabetes drug has in patients with Li Fraumeni Syndrome (LFS), a genetic condition that impacts 1 in 20,000 people worldwide and puts them at a 70-90% lifetime risk of cancer.